



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number: 0 431 945 A2

⑫

EUROPEAN PATENT APPLICATION

㉑ Application number: 90313264.5

㉒ Date of filing: 06.12.90

㉓ Int. Cl.5: C07D 401/06, C07D 211/32,
C07D 409/12, C07D 409/14,
C07D 335/06, C07D 295/116,
C07D 213/38, C07D 295/135,
C07D 295/096, C07D 233/60,
C07D 495/04, // (C07D495/04,
335:00,333:00)

㉔ Priority: 08.12.89 US 447949

㉕ Date of publication of application:
12.06.91 Bulletin 91/24

㉖ Designated Contracting States:
CH DE FR GB IT LI NL

㉗ Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065-0900(US)


㉘ Inventor: Baldwin, John J.
621 Gypsy Hill Circle
Gwynedd Valley, PA 19437(US)
Inventor: Claremon, David A.
809 Mockingbird Lane
Audubon, PA 19403(US)

Inventor: Elliott, Jason M.
74 Ramsgate Court
Blue Bell, PA 19422(US)
Inventor: Ponticello, Gerald S.
2045 Spring Valley Road
Lansdale, PA 19446(US)
Inventor: Remy, David C.
607 Jenkins Lane, MR1
North Wales, PA 19454(US)
Inventor: Selnick, Harold G.
1232 Lois Road
Ambler, PA 19002(US)

㉙ Representative: Hesketh, Alan, Dr. et al
European Patent Department Merck & Co.,
Inc. Terlings Park Eastwick Road
Harlow Essex, CM20 2QR(GB)

㉚ Antiarhythmic agents.

㉛ Compounds of structural formula:



wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members and Q is a nitrogen containing heterocycle, are antiarrhythmic agents.

EP 0 431 945 A2


ANTIARRHYTHMIC AGENTS

SUMMARY OF THE INVENTION

This invention is concerned with novel compounds of the class with structural formula:

5

10



or a pharmaceutically acceptable salt thereof, wherein Ar is an aromatic ring, B is a 5-7 membered cyclic moiety fused to Ar, and X and Y are bridging groups such as alkylene, Q is a 5-7 membered nitrogen heterocycle such as piperidine or piperazine and R¹ is an aryl group. These compounds are useful in the treatment of arrhythmia.

The invention is also concerned with novel processes for preparing the novel compounds; pharmaceutical formulations comprising one or more of the novel compounds as an active antiarrhythmic agent either alone or in combination with other cardiovascular agents such as a β -blocker or other antiarrhythmic agent; and a method of treating arrhythmia by administration of one of the novel compounds or formulations thereof to a patient in need of such treatment.

BACKGROUND OF THE INVENTION

25 Arrhythmias often occur as complications to cardiac diseases such as myocardial infarction and heart failure. In a serious case, arrhythmias give rise to a ventricular fibrillation and can cause sudden death.

Though various antiarrhythmic agents are now available on the market, those having both satisfactory effects and high safety have not been obtained. For example, antiarrhythmic agents of Class I according to the classification of Vaughan-Williams which cause a selective inhibition of the maximum velocity of the 30 upstroke of the action potential (Vmax) are inadequate for preventing ventricular fibrillation. In addition, they have problems regarding safety, namely, they cause a depression of the myocardial contractility and have a tendency to induce arrhythmias due to an inhibition of the impulse conduction. Beta-adrenoceptor blockers and calcium antagonists which belong to Class II and IV respectively, have a defect that their effects are either limited to a certain type of arrhythmia or are contraindicated because of their cardiac depressant 35 properties in certain patients with cardiovascular disease. Their safety, however, is higher than that of the antiarrhythmic agents of Class I.

Antiarrhythmic agents of Class III are drugs which cause a selective prolongation of the duration of the action potential without a significant depression of the Vmax. Drugs in this class are limited. Examples such as sotalol and amiodarone have been shown to possess Class III properties. Sotalol also possesses Class II 40 effects which may cause cardiac depression and be contraindicated in certain susceptible patients. Also, amiodarone is severely limited by side effects. Drugs of this class are expected to be effective in preventing ventricular fibrillations. Pure class III agents, by definition, are not considered to cause myocardial depression or an induction of arrhythmias due to the inhibition of the action potential conduction as seen with Class I antiarrhythmic agents.

45 A number of antiarrhythmic agents have been reported in the literature, such as those disclosed in:

- (1) EP 397,121-A, (2) EP 300,908-A; (3) EP 307,121,
- (4) US 4,629,739, (5) US 4,544,654, (6) US 4,788,196,
- (7) EP application 88302597.5,
- (8) EP application 88302598.3,
- (9) EP application 88302270.9,
- (10) EP application 88302600.7,
- (11) EP application 88302599.1,
- (12) EP application 88300962.3,
- (13) EP application 235,752,
- (14) DE 3633977-A1,


(15) US 4,804,662,
 (16) US 4,797,401,
 (17) US 4,806,555,
 (18) US 4,806,536.

5

DETAILED DESCRIPTION OF THE INVENTION

The novel compounds of this invention have structural formula:

10



15

or a pharmaceutically acceptable salt thereof, wherein:

Ar is an aromatic ring selected from;

- 1) benzo,
- 2) thieno, and
- 3) furo, and
- 4) pyrrolo;

B is benzo or other carbocyclic or heterocyclic moiety of 5-7 members fused to the aromatic ring, Ar, with up to 3 variable members independently selected from:

- 1) S-(O)_p, wherein p is 0, 1, or 2,
- 2) C(R)₂ wherein the R groups are the same or different and represent hydrogen or C₁-6 alkyl,
- 3) C=O,
- 4) CHOR,
- 5) -O-, and
- 6) NR;

Q is a 5-7 membered heterocycle with one or two nitrogen atoms such as piperidine, piperazine, pyrrolidine, imidazolidine, hexahydroazepine, hexahydrodiazepine, or imidazole;

X is -CO-, -CONR(CR₂)_m-, -SO₂- or -(CR₂)_{-m};

Y is -(CR₂)_mO-; wherein m is 0, 1, 2 or 3;

R¹ is hydrogen if Q is imidazolyl or if Q is other than imidazolyl, R¹ is pyridyl, benzimidazolyl, pyrimidinyl, phenyl, naphthyl, thienyl, thiazolyl, pyrazinyl, quinolinyl, quinoxalinyl, indolyl, or benzofuranyl, either unsubstituted or substituted with one or more of R², R³ and/or R⁵, wherein:

R⁵ is

- 1) -N(R)SO₂ C₁-6alkyl,
- 2) -N(R)SO₂(CH₂)_mCO₂C₁-6alkyl,
- 3) -NO₂;
- 4) -N(R)COC₁-6alkyl,
- 5) -N(R)SO₂-C₆H₄-R
- 6) -N(R)COC₆H₄-R
- 7) -C₂-6 alkanoyl,
- 8) CON(R)₂
- 9) -CN,
- 10) -CO₂C₁-6alkyl

45 11) benzoyl, either unsubstituted or substituted with C₁-6alkyl, C₁-6alkoxy, halo such as Cl, Br, F, or I or hydroxy

12) -NRCOO(C₁-6alkyl),

50 13) -NRCOOphenyl either unsubstituted or substituted with C₁-6alkyl, C₁-6alkoxy, hydroxy or halo asuch as Cl, F Br, or I,

14) -NRCON(R)₂,

55 15) -S(O)_pC₁-6alkyl wherein p is 0, 1 or 2,

16) -S(O)_pphenyl, either unsubstituted or substituted with C₁-6alkyl, C₁-6alkoxy, hydroxy, or

halo such as F, Cl, Br, or I,

17) phenyl, either unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halo such as Cl Br, E, or I, or hydroxy,

18) imidazolyl, or

5 19) SO₂NR₂;

R² and R³ are independently selected from:

1) hydrogen.

2) C₁₋₃alkyl either unsubstituted or substituted with
a)-N(R)₂

10 b)-CON(R)₂

c)-CO(C₁₋₆alkyl),

d)-O(C₁₋₆alkyl),

e)-OH, or

f)-S(O)p(C₁₋₆alkyl);

15 3) C₁₋₃ alkoxy,

4) -N(R)₂,


5) halo such as Cl, Br, F, or I, or

6) CF₃.

with the proviso that if R¹ is phenyl, with other than an R⁵ substituent, then one of R² or R³ in the

20


25



One embodiment of the novel compounds of this invention comprises those wherein Q represents a 5-7 membered heterocycle and has a subgeneric structure

30

35



wherein Z is

40




especially wherein Q represents piperazine or piperidine.

It is preferred that Ar be benzo or thieno and that B have the structure:


45

50




55

5


10. wherein W is C=O, CH₂ or CHOH.

It is even more preferred that B have the structure:

15



20



25

It is also preferred that R¹ be pyridyl, benzimidazolyl, pyrimidinyl or phenyl, either unsubstituted or substituted with R², R³ and/or R⁵, especially 2-pyridyl, 6-methyl-2-pyridyl, or 4-methanesulfonamidophenyl.

The term "alkyl", if the number of carbons is unspecified, means C₁-alkyl and "alkyl" of three or more carbon atoms includes straight chain, branched chain and cycloalkyl.

30. Also included within the scope of the present invention are the non-toxic pharmaceutically acceptable salts of the novel compounds. Acid addition salts are formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, phosphoric acid, or the like.

Also included within the scope of this invention are diastereomers and enantiomers of the novel 35 compounds and mixtures thereof.

The novel processes of this invention can be exemplified by the following reaction schemes.


40

45

50

55

5



10

15

20

25

30


35

40

45

50

55



35 The process of Scheme I comprises addition of the piperidine across the vinyl group by heating a mixture of 1 part of the piperidine compound with about 1-2 parts of the vinyl compound in an aqueous lower alkanol such as methanol or ethanol in the presence of 1-2 parts of sodium or potassium acetate for about 10-20 hours at about reflux temperature.

Reaction Scheme II comprises N-alkylation of the piperidine molecule with a slight excess of the phenalkyl alkylating agent. Although the leaving group exemplified is bromo, equivalent leaving groups are chloro, mesyl, tosyl, or the like. The two reagents are heated at about reflux temperature in a suitable solvent, preferably one in which the reagents are soluble such as, in this case a lower alkanol, such as methanol, ethanol or propanol in the presence of an acid scavenger such as sodium or potassium bicarbonate or carbonate, an organic amine or an appropriate ion exchange resin for about 45 to 96 hours.

45 The process of Scheme III is similar to that of Scheme II except that a more suitable solvent is acetone, acetonitrile or methanol.

Scheme IV depicts alterations of substituents such as reduction of an aromatic nitro group to an amino which can be accomplished with standard reducing agents known in the art such as stannous chloride, or titanium trichloride, followed by sulfonylation with an alkanesulfonyl chloride by standard procedures.

50 Similarly reaction Scheme V is reduction of the tetralone carbonyl with a complex hydride such as lithium or sodium borohydride in methanol or lithium aluminum hydride in THF.

55 significant depression of the Vmax and with the prolongation of QTc-interval in anesthetized dogs. Moreover, the effects of many of the novel compounds are much more potent than the reference drug, sotalol.

The compounds of the present invention are effective in treating and preventing all types of arrhythmias including ventricular and atrial (supraventricular) arrhythmias. The compounds of the present invention are

especially useful to control reentrant arrhythmias and prevent sudden death due to the ventricular fibrillation.

In the novel method of this invention of treating arrhythmia, a novel compound or pharmaceutically acceptable salt thereof, is administered in an amount ranging from about 0.0001 to about 20 mg per kg of body weight per day, preferably from about .001 to about 10 mg per kg of body weight per day in a single dose or in 2 to 4 divided doses.

5 The novel compounds of this invention can be administered as the sole active ingredient or in combination with other antiarrhythmic agents or other cardiovascular agents.

10 The compounds, or pharmaceutically acceptable salts thereof, of the present invention, in the described dosages, are administered orally, intraperitoneally, subcutaneously, intramuscularly, transdermally, sublin-
gually or intravenously. They are preferably administered orally, for example in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum, or the like prepared by art recognized procedures. The amount of active compound in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained.

15 **EXAMPLE 1**

2-[1-(2-Pyridylethyl)-4-piperidyl]-1-indanone dihydrochloride.

Step A: Preparation of 2-(4-piperidyl)-1-indanone hydrochloride

To a solution of 2.73 g (0.0119 mol) of 2-(1-methyl-4-piperidyl)-1-indanone in 100 ml of 1,2-dichloroethane cooled in an ice bath was added 1.72 g (0.012 mol) of α -chloroethyl chloroformate dropwise. The 20 solution was allowed to warm to room temperature and then was refluxed for 2 hours. TLC indicated the reaction was not complete. An additional 0.86 g (0.006 mol) of α -chloroethyl chloroformate was added to the cooled mixture, after which it was refluxed for 2 hours. The 1,2-dichloroethane was removed under reduced pressure, and the residue was chromatographed on silica gel using ethyl acetate as an eluant. Evaporation of the eluant gave 1.90 gm of a clear oil. The oil was dissolved in 50 mL of methanol and was refluxed for 10 hours. Evaporation of the methanol afforded 1.60 g of 2-(4-piperidyl)-1-indanone hydrochloride.

Step B: Preparation of 2-[1-(2-pyridylethyl)-4-piperidyl]-1-indanone dihydrochloride

30 A mixture of 0.251 g (0.001 mol) of 2-(4-piperidyl)-1-indanone hydrochloride, 0.21 g (0.002 mol) of 2-vinylpyridine, 0.272 g (0.002 mol) sodium acetate trihydrate, 2 mL of water, and 2 mL of methanol was stirred and refluxed for 20 hours. The solvent was evaporated in vacuo and the residue was dissolved in ethyl acetate and dried over magnesium sulfate. The product was isolated in pure form by chromatography on silica gel using 5% methanol in chloroform. A hydrochloride salt was prepared and was recrystallized 35 from ethanol to give 2-[1-(2-pyridylethyl)-4-piperidyl]-1-indanone dihydrochloride, mp 195-196 °C.

Anal. Calcd. for $C_{21}H_{24}N_2O \cdot 2HCl \cdot 0.4H_2O$:

C, 62.97; H, 6.74; N, 6.99.

40 **Found C, 63.05; H, 6.61; N, 6.90.**

EXAMPLE 2

45 2-[1-(4-Nitrophenethyl)-4-piperidyl]-1-indanone dihydrochloride.

A mixture of 0.46 g (0.00183 mol) of 2-(4-piperidyl)-1-indanone hydrochloride, 0.578 g (0.00251 mol) of 50 p-nitrophenethyl bromide, 0.422 g (0.00502 mol) sodium bicarbonate and 20 mL of ethanol was stirred and refluxed for 72 hours. The ethanol was removed by evaporation, and the residue was partitioned between ethyl acetate and water. The ethyl acetate phase was washed with water, dried over magnesium sulfate, filtered, and the ethyl acetate removed. The residue was purified by chromatography on silica gel using 2.5% methanol in chloroform as an eluant. Evaporation of the solvent gave a crystalline product that was converted to a hydrochloride salt. Recrystallization from ethanol gave 2-[1-(4-nitrophenethyl)-4-piperidyl]-1-indanone hydrochloride, mp 259-261 °C.

Anal. Calcd. for $C_{22}H_{24}N_2O_3 \cdot HCl \cdot 0.25H_2O$:
 C, 65.18; H, 6.34; N, 6.91.
 Found C, 65.21; H, 6.06; N, 6.78.

5

EXAMPLE 3

2-[1-(4-Methanesulfonamidophenethyl)-4-piperidyl]-1-indanone hydrochloride.

10

A mixture of 0.54 g (0.0022 mol) of 2-(4-piperidyl)-1-indanone hydrochloride, 0.73 g (0.0025 mol) of 2-[4-(methanesulfonamidophenyl)-1-ethanol methanesulfonate, 0.45 g (0.0054 mol) of sodium bicarbonate and 20 mL of ethanol was stirred and refluxed for 14 hours. The ethanol was removed and the residue was dissolved in ethyl acetate. This solution was washed with water, dried over $MgSO_4$, filtered, and the solvent removed. A hydrochloride salt was prepared and was recrystallized from ethanol to give 2-[1-(4-methanesulfonamidophenethyl)-4-piperidyl]-1-indanone hydrochloride, m.p. 258-261 °C.

15

Anal. Calcd. for $C_{23}H_{28}N_2O_3S \cdot HCl \cdot 0.25H_2O$:
 C, 60.91; H, 6.56; N, 6.18.
 Found C, 60.83; H, 6.42; N, 6.16.

25

EXAMPLE 4

4-{{4-(2-Pyridylethyl)}-1-piperazinyl}thiochromane trihydrochloride:

Thionyl chloride (4 mL) was added to 0.50 g (0.003 mol) of thiochroman-4-ol. After the reaction had subsided, the excess thionyl chloride was removed on a rotary evaporator. The residue was dissolved in 20 mL of acetone, and 0.67 g (0.0035 mol) of 4-(2-pyridylethyl)piperazine and 0.57 g (0.00415 mol) of powdered potassium carbonate were added. The stirred mixture was refluxed for 46 hours. The acetone was removed by evaporation and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water, dried over $MgSO_4$, filtered, and the solvent removed to afford 1.01 g of clear oil. Flash chromatography on silica gel using 3% methanol in chloroform gave 4-{{4-(2-pyridylethyl)}-1-piperazinyl}thiochromane. A hydrochloride salt was prepared and recrystallized from ethanol: m.p. 183-185 °C.

40

Anal. Calcd. for $C_{20}H_{25}N_3S \cdot 3HCl \cdot H_2O$:
 C, 51.45; H, 6.48; N, 9.00.
 Found C, 51.47; H, 6.52; N, 8.95.

45

EXAMPLE 5

4-{{4-(p-Nitrophenethyl)-1-piperazinyl}}thiochromane hydrochloride.

Thionyl chloride (5 mL) was added to 1.0 g (0.006 mol) of thiochroman-4-ol. After the reaction had subsided the excess thionyl chloride was removed on a rotary evaporator. To the residue was added 1.64 g (0.007 mol) of 4-(p-nitrophenethyl)piperazine, 1.14 g (0.0083 mol) of powdered potassium carbonate, and 30 mL of acetone. The mixture was stirred and refluxed for 40 hours. The acetone was removed by evaporation in vacuo and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water, dried over $MgSO_4$, filtered, and the solvent removed. Flash chromatography of the residue on silica gel using 3% methanol in chloroform gave 0.47 g of crystalline material. A hydrochloride salt, prepared in ethanol, was recrystallized from water to give the intermediate 4-{{4-(p-nitrophenethyl)-1-piperazinyl}}-thiochromane hydrochloride, m.p. 214-215 °C.

Anal. Calcd. for $C_{21}H_{25}N_3O_2S \cdot HCl \cdot 0.5H_2O$:
 C, 58.82; H, 6.34; N, 9.80.
 Found C, 58.92; H, 6.26; N, 9.80.

5

EXAMPLE 6

N-[4-(4-Thiochromanyl)-1-piperazinyl]ethylphenyl] methanesulfonamide

10

To a solution of 1.0 g (0.00261 mol) of 4-[[4-(p-nitrophenethyl)-1-piperazinyl]thiochromane in 25 mL of ethyl acetate was added 2.5 g of stannous chloride dihydrate. The mixture was stirred 30 minutes at room temperature and then was refluxed for 30 minutes. An additional 2.5 gm of stannous chloride dihydrate was added and the mixture was refluxed an additional hour. To the cooled solution was added 50 ml of 20% aqueous sodium hydroxide solution. The mixture was stirred vigorously, and the ethyl acetate was decanted. The mixture was re-extracted with ethyl acetate and the combined extracts were washed with water, dried ($MgSO_4$), and filtered. Evaporation of the solvent gave 0.68 gm (74%) of a clear oil. This oil was dissolved in 3 mL of methylene chloride and was treated with 0.25 g (0.00212 mol) of methanesulfonyl chloride. After stirring at room temperature for 4 hours, the solvent was evaporated and the residue was converted to a hydrochloride salt. Recrystallization from methanol gave the title compound; m.p. 213-215 °C.

15

20

Anal. Calcd. for $C_{22}H_{29}N_3O_2S_2 \cdot 2HCl$:
 C, 52.37; H, 6.19; N, 8.33.
 Found C, 52.39; H, 6.25; N, 8.28.

30

EXAMPLE 7

2-[4-(4-Nitrophenethyl)-piperazin-1-yl]-1-tetralone

Method A: To a solution of 4.7 g (0.002 mole) 1-(p-nitrophenethyl)piperazine and 0.25 g (0.0025 mole) triethylamine in 10 ml acetone was added 0.45 g (0.002 mole) 2-bromo- α -tetralone. The solution was stirred under N_2 at room temperature for 16 hours. The mixture was filtered. The solid was treated with saturated $NaHCO_3$ solution and extracted with CH_2Cl_2 . The CH_2Cl_2 solution was dried over Na_2SO_4 , filtered and concentrated. The solid residue was dissolved in CH_2Cl_2/CH_3OH and acidified with ethanolic HCl. The solvent was removed in *vacuo* the resulting solid residue was treated with boiling ethanol. The dihydrochloride was filtered off and dried to give 0.095 g (10.5% yield) m.p. 222-223 °C.


40

45

Anal. Calcd. for $C_{22}H_{25}N_3O_3 \cdot 2HCl \cdot 3/4H_2O$:
 C, 56.71; H, 6.17; N, 9.02.
 Found C, 56.64; H, 6.12; N, 9.06.

Method B: A solution of 2.25 g (0.01 mole) 2-bromo- α -tetralone and 2.35 g (0.01 mole) 1-(p-nitrophenethyl)-piperazine in 15 ml acetone was stirred and heated at reflux for 6 hours. The mixture was filtered and treated as in Method A. 1.06 g (28% Yield) free base was obtained.

Employing the procedure substantially as described in Example 7, but substituting for the 2-bromo- α -tetralone and the 1-(p-nitrophenethyl)-piperazine used therein the tetralones and piperazines described in Table I there were produced the piperazinyl tetralones also described in Table I in accordance with the following reaction scheme:



15

20

25

30

35

40








45

50

55

TABLE I

5

Example	R ²	R ³	-Y-R ¹	salt	m.p. (°C)
10					
15	8	H	H		3HCl•0.75H ₂ O 196-199
20	9	NO ₂ ⁽¹⁾	H		2HCl•0.5H ₂ O 245-248
25	10	H	H		2HCl•0.5H ₂ O 166-169.5
30	11	NO ₂ ⁽¹⁾	H		HBr•0.5H ₂ O 234-236
35	12	NO ₂ ⁽¹⁾	H		3HCl 171-181
40	13	CH ₃ SO ₂ NH ⁻ (1)	H		2HCl•0.5H ₂ O 216-219.5
45	14	CH ₃ SO ₂ NH ⁻ (1)	H		2HCl 226-229
50	15	H	CH ₃ SO ₂ NH ⁻ (1)		HBr 286 (dec.)

55

5 (1) The 2-bromo-6- and 7-nitro and methanesulfon-
 amido compounds required as starting materials are
 prepared as described below for 2-bromo-7-nitro-1-
 tetralone and 2-bromo-7-methansulfonamido-
 α -tetralone.

10 7-Amino-1-tetralone:

15 A solution of 2 g (0.0105 mole) 7-nitro-1-tetralone in 120 ml ethanol was hydrogenated under < 5 psi H₂ pressure using Raney Ni as catalyst. The solution was filtered with the aid of super gel and concentrated under reduced pressure to give the 7-amino-1-tetralone.

20 7-Methanesulfonamide-1-tetralone:

25 To a solution of 7-amino-1-tetralone in 30 ml CH₂Cl₂ was added 1.03 g (0.013 mole) pyridine and 1.33 g (0.0116 mole) methanesulfonyl chloride. The solution was stirred at room temperature for 3 hours, saturated NaHCO₃ solution was added. The CH₂Cl₂ solution was separated and washed with H₂O. The resulting solution was dried over Na₂SO₄ (anhydrous), filtered, concentrated in vacuo and recrystallized from abs. ethanol to give 1.45 g (58% yield) of 7-methanesulfonamido-1-tetralone.

30 2-Bromo-7-nitro-1-tetralone:

35 To a suspension of 9.56 g (0.05 mol) of 7-nitro-1-tetralone in 250 mL of ether was added bromine dropwise. The progress of the reaction was followed by thin layer chromatography (fl. silica gel/CH₂Cl₂). When all of the starting material had been consumed, the mixture was concentrated and cyclohexane was added. The white solid was removed by filtration to afford 2.25 g of 2-bromo-7-nitrotetralone, mp 94-96 °C.

2-Bromo-7-methanesulfonamido-1-tetralone:

40 To a solution of 1.4 g (0.00585 mol) of 7-methanesulfonamidotetralone in 20 mL of methylene chloride was added dropwise a solution of 0.94 g (0.0059 mol) of bromine in 5 mL of methylene chloride. The progress of the reaction was followed by thin layer chromatography (fl. silica gel/CH₂Cl₂). A few additional drops of the bromine solution were added to completely consume the starting material. The solution was evaporated to dryness to give 2.0 g of 2-bromo-7-methanesulfonamido-1-tetralone, mp 87-92 °C.

45 EXAMPLE 18
1-Hydroxy-2-[4-(4-nitrophenethyl)piperazin-1-yl]-tetralin

50 To a solution of 0.13 g (0.00034 mole) 2-[4-(4-nitrophenethyl)-piperazin-1-yl]-1-tetralone in 30 ml CH₃OH was added 0.081 g (0.00214 mole) sodium borohydride in small portions. The solution was stirred at room temperature for 17 hours. The solvent was removed under reduced pressure. Water was added to the residue. Crude solid product was filtered off and recrystallized from ethyl acetate/ n-hexane to give 30 mg product. NMR and TLC of this material indicated it to be a mixture of 2 isomers. HPLC showed the isomer ratio to be 50-48. This mixture was converted to its dihydrochloride. m.p. 155-159 °C.

55 Anal. Calcd. for C₂₂H₂₆N₃O₃•2HCl:
C, 57.14; H, 6.32; N, 9.09.
Found C, 57.39; H, 6.47; N, 8.94.

55

EXAMPLE 17

1-Hydroxy-2-[4-(2-pyridyl-2-ethyl)piperazin-1-yl] tetralin·3HCl·0.75 H₂O, m.p. 220-223 °C (isomer ratio 52:45) was prepared employing the procedure substantially as described in Example 16.

EXAMPLE 18

5 5,6-Dihydro-5-[4'-(2-(2-pyridyl)ethyl)piperazin-1'-yl] methylthieno[2,3-b]thiopyran-4-one trihydrochloride hemihydrate

Step A: Preparation of 5,6-dihydro-5-dimethylaminomethylthieno[2,3-b]thiopyran-4-one hydrochloride

A mixture of 5,6-dihydrothieno[2,3-b]thiopyran-4-one (12.5 g, 0.074 mol), paraformaldehyde (7.5 g, 0.25 mol), dimethylamine-hydrochloride (40 g, 0.49 mol) and acetic acid (2 ml) was heated with stirring at 100 °C for 1 hour. After allowing to cool to room temperature, the solid was triturated with ethanol and the solid was collected on a filter to yield 16.3 g (83%) of the title compound. An analytical sample was prepared by crystallization from 95% ethanol and filtration through a pad of norite-ducco-supercel to yield product with mp 155-157 °C. Anal. Calc'd. for C₁₀H₁₃NOS₂·HCl.

15

	<u>Calc'd</u>	<u>Observed</u>
	C 5.31	5.42
20	H 41.53	45.12
	N 5.35	5.37

25 Step C: Preparation of 5,6-dihydro-5-[4'-(2-(2-pyridyl)ethyl)piperazin-1'-yl]methylthieno-[2,3-b]thiopyran-4-one trihydrochloride hemihydrate.

Under N₂, a mixture of product from Step B (0.26 g, 0.0014 mol); 1-(2-(2-pyridyl)ethyl)piperazine (0.35 g, 0.0018 mol) and Al₂O₃ (0.35 g) in benzene (10 ml) was stirred at room temperature. After 18 hours, the mixture was filtered, and the solution concentrated to dryness. The residue was chromatographed on silica gel (Still column, 50 mm) and the product was eluted with 5% methanol/ chloroform to 60 mg (9%) of free base. The compound was crystallized as the HCl salt from ethanol to yield 4; mp 165 °C. Anal. Calc'd. for C₁₉H₂₃N₃OS₂·3HCl $\frac{1}{2}$ H₂O

35

	<u>Calc'd</u>	<u>Observed</u>
	N 8.39	8.54
40	C 46.25	46.38
	H 5.60	5.53

EXAMPLE 19

45 5,6-Dihydro-5-[N-2-methylimidazoyl]methylthieno-[2,3-b]thiopyran-4-one

Under N₂, a mixture of 5,6-dihydro-5-methylenethieno[2,3-b]thiopyran (0.55 g, 0.003 mol), 2-methylimidazole 0.25 g, 0.006 mol), Al₂O₃ act. III (0.7 g) in benzene (15 ml) was stirred at room temperature. After 4 hours, the reaction was filtered and the solid was washed with ethylacetate. The organic filtrate was washed with H₂O dried, filtered and concentrated to dryness. The residue was chromatographed on silica gel (Still column, 50 mm). The product was eluted with 2.5% CH₃OH-CHCl₃ with 0.25% aq. NH₃. The compound was crystallized from CH₂Cl₂-n-butyl chloride to yield 0.19 g (24%) of product, mp 135-136 °C. Anal. Calc'd. for C₁₂H₁₆N₂OS₂.

55

	<u>Calc'd</u>	<u>Observed</u>
5	N 10.6	10.49
	C 54.52	54.12
	H 4.58	4.49

10 EXAMPLE 20

2-(N-2-methylimidazoyl)methyl-6-methoxytetral-1-one

Step A: Preparation of 2-dimethylaminomethyl-6-methoxytetral-1-one

Under N_2 , a mixture of 6-methoxytetral-1-one (0.45 g, 0.0028 mol), paraformaldehyde (0.28 g, 0.0095 mol), dimethylamine-hydrochloride (1.5 g, 0.018 mol) and acetic acid (0.8 ml) was heated at 100 $^{\circ}C$. After 1.5 hours, the reaction was cooled to room temperature, the solid was triturated with ethanol, filtered and the solids collected to yield 0.5 g (77%) of product.

Step B: Preparation of 2-methylene-6-methoxytetral-1-one

20 Under N_2 , a mixture of product from Step A (0.21 g, 0.0009 mol) in DMF (25 ml) was heated at 100 $^{\circ}C$. After 1 hour, the reaction was cooled to room temperature, poured in H_2O , and extracted with ethyl acetate (3x). The organic layer was washed with H_2O , saturated NaCl, dried, filtered and concentrated to dryness to yield 170 mg (100%) of product.

25 Step C: Preparation of 2-(N-2-methylimidazoyl)methyl-6-methoxytetral-1-one

A mixture of product from Step B (170 g, .001 mol), 2-methylimidazole (0.08 g, 0.001 mol), Al_2O_3 act. III (0.25 g) in benzene (5 ml) was stirred at room temperature. After 2 hours, 2-methylimidazole (0.08 g) was 30 added and the reaction stirred at room temperature. After 18 hours, the reaction was filtered through super cel and the filter pad washed with ethylacetate. The organic layer was washed with H_2O , dried, filtered and concentrated to dryness. The residue was chromatographed on silica gel (Still column, 20 mm) and the product eluted with 5% CH_3OH - $CHCl_3$. The solid was crystallized from CH_2Cl_2 -n- butyl chloride to yield 0.13 g (48%) of product; mp 163-165 $^{\circ}C$. Anal. Calc'd. for $C_{16}H_{18}N_2O_2$.

35

	<u>Calc'd</u>	<u>Observed</u>
40	N 10.36	10.16
	C 71.09	70.79
	H 6.71	6.49

45 EXAMPLE 21

5,6-Dihydro-4H-4-hydroxy-5-[(2-methyl-1H-imidazol-1-yl)-methyl]thieno[2,3-b]thiopyran(α -Isomer, and β -Isomer)

Sodium borohydride, 0.22 g (0.0057 m) was added to a stirred solution of 5,6-dihydro-5-[(2-methyl-1H-imidazol-1-yl)methyl]thieno[2,3-b]thiopyran-4-one, 1.14 g (0.0043 m), in absolute ethanol (45 ml). After refluxing for 2.5 hours, the mixture was treated with 5% sodium hydroxide solution (10 ml) and concentrated in vacuo to remove ethanol. The residue was distributed between ethyl acetate (50 ml) and water (25 ml), the aqueous layer was separated and extracted with ethyl acetate (2 x 35 ml). The combined extracts were washed twice with water, dried over sodium sulfate and concentrated in vacuo to yield 0.83 g (72%) of 55 amorphous tan solid of a mixture of α and β -isomers. The mixture was chromatographed on a 50 mm diameter flash column using silica gel 60 (E. Merck 230-400 mesh) and eluting with 1% methanol/ $CHCl_3$ saturated with ammonia. The α -isomer weighed 0.18 g and melted at 240-241.5 $^{\circ}C$ after recrystallization from ethanol. Anal. Calc'd. for $C_{12}H_{14}N_2OS_2$: C, 54.11; H, 5.30; N, 10.52 Found: C, 53.89; H, 5.11; N, 10.37.

The β -isomer weighed 0.30 g and melted at 155.5-157.5 $^{\circ}$ C after recrystallization from ethanol-water. Anal. Calc'd. for C₁₂H₁₄N₂OS₂: C, 54.11; H, 5.30; N, 10.52. Found: C, 53.87; H, 5.18; N, 10.38. Based on PMR studies, the α -isomer is cis, and the β -isomer is trans.

5 EXAMPLE 22

6-Methanesulfonamido-2-(1-[2-pyridylethyl]-4-piperidyl)indan-1-one dihydrochloride

Step A: Preparation of 6-Nitro-2-(1-methyl-4-piperidyl)-1-oxo-2-indanecarboxamide

To an ice cold solution of 2-(1-methyl-4-piperidyl)-1-oxo-2-indanecarboxamide hydrochloride (5.5 g, 0.0178 mol) in 27 mL of concentrated sulfuric acid was added dropwise over 5 minutes 2.20 g of 90% nitric acid dissolved in 6.8 mL of cold concentrated sulfuric acid. After the addition was complete, the solution was stirred at 0 $^{\circ}$ C for two hours and then was poured onto ice. The solution was made basic by the addition of solid sodium bicarbonate, and the mixture was extracted with three 100 mL portions of chloroform. The combined chloroform extracts were washed with water, dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was recrystallized from absolute ethanol to give 4.42 g (78% yield) of 6-nitro-2-(1-methyl-4-piperidyl)-1-oxo-2-indane carboxamide, mp 189-190 $^{\circ}$ C.

Anal. Cal'd. for C₁₆H₁₉N₃O₄: C, 60.55; H, 6.04; N, 13.24. Found: C, 60.72; H, 6.05; N, 13.18.

20 Step B: Preparation of 6-Nitro-2-(1-methyl-4-piperidyl)-indan-1-one

A solution of 4.42 g of 6-nitro-2-(1-methyl-4-piperidyl)-1-oxo-2-indanecarboxamide in 60 mL of 6N hydrochloric acid was stirred and refluxed for one hour. The solution was cooled in an ice bath and made basic by the addition of 20% aqueous sodium hydroxide. The mixture was extracted with three 100 mL portions of ether. The combined extracts were dried over magnesium sulfate, filtered, and the ether was removed under reduced pressure to give 3.72 g (97%) of 6-nitro-2-(1-methyl-4-piperidyl)-indan-1-one as a low melting crystalline solid.

30 Step C: Preparation of 6-Nitro-2-(4-piperidyl)indan-1-one hydrochloride

To a stirred, ice-cooled solution of 0.71 g (0.00259 mol) of 6-nitro-2-(1-methyl-4-piperidyl)-indan-1-one in 20 mL of 1,2-dichloroethane was added 0.67 g (0.0052 mol) of diisopropylethylamine and 0.74 g (0.0052 mol) of 1-chloroethyl chloroformate. After the addition was complete, the solution was refluxed for one hour. The cooled solution was washed with two portions of 2N HCl, water, and then was dried over magnesium sulfate. After filtration, the solvent was removed under reduced pressure. The residual oil was purified by filtration through a silica gel column using ethyl acetate to elute the column. Evaporation of the eluant gave 0.95 g (100%) of the intermediate urethane. A solution of 2.0 g of this urethane in 100 mL of absolute methanol was stirred and refluxed for one hour. Evaporation of the methanol gave 6-nitro-2-(4-piperidyl)-indan-1-one hydrochloride. The solid was triturated with isopropyl alcohol and was collected by filtration to give 1.25 g (81%) of product.

Step D: Preparation of 6-Nitro-2-(1-[2-pyridyl-ethyl]-4-piperidyl)indan-1-one

A mixture of 0.60 g (0.0020 mol) of product from Step C, 0.22 g (0.0040 mol) of 2-vinylpyridine and 0.28 g (0.0040 mol) of sodium acetate trihydrate in 8 mL of aqueous methanol (1:1 v:v) was stirred and refluxed for 7 hours. An additional 0.106 g of 2-vinylpyridine and 0.14 g of sodium acetate trihydrate was added, and the mixture was stirred and refluxed for 9 hours. The mixture was evaporated to dryness, and the residue was extracted with chloroform. Evaporation of the chloroform extracts gave 0.70 g of oil that was purified by flash chromatography on silica gel using 5% CH₃OH in chloroform to elute the column. Evaporation of the eluate gave 0.40 g of 6-nitro-2-(1-[2-pyridylethyl]-4-piperidyl)indan-1-one.

Step E: Preparation of 6-Methanesulfonamido-2-(1-[2-pyridylethyl]-4-piperidyl)indan-1-one

A solution of 0.40 g of product from Step D in 20 mL of ethanol and 20 mL of tetrahydrofuran was hydrogenated at 10 psi over Raney nickel catalyst. After 2 hours, the catalyst was removed by filtration, and the solvent was removed under reduced pressure to give 0.35 g of crystalline 6-amino-2-(1-[2-pyridylethyl]-4-piperidyl)indan-1-one.

Step F:

To a solution of 0.35 g (0.00104 mol) of product from Step E in 5 mL of pyridine was added 0.131 g (0.00115 mol) of methanesulfonyl chloride. After stirring at room temperature for one hour, the pyridine was removed under reduced pressure. After adding 10 mL of an aqueous saturated sodium bicarbonate solution to the residue, it was extracted with three portions of ethyl acetate. These extracts were combined and dried over $MgSO_4$. Removal of the solvent afforded 0.374 g (87%) of the free base of the product. A hydrochloride salt was prepared and recrystallized from methanol to give 6-methanesulfonamido-2-(1-[2-pyridylethyl]-4-piperidyl)indan-1-one dihydrochloride \cdot 0.5H₂O: mp 224-226 °C.

10 Anal. Cal'd. for $C_{22}H_{27}N_3O_3S\cdot 2HCl\cdot 0.5H_2O$: C, 53.33; H, 6.10; N, 8.48. Found: C, 53.11; H, 5.76; N, 8.40.

EXAMPLE 23**6-Methanesulfonamido-2-(1-[4-methanesulfonamidophenethyl]-4-piperidyl)indan-1-one hydrochloride**Step A: Preparation of 6-Methanesulfonamido-2-(1-methyl-4-piperidyl)indane-1-one

A solution of 1.86 g (0.0068 mol) of 6-nitro-2-(1-methyl-4-piperidyl)indan-1-one in 50 mL of absolute ethanol and 50 mL of tetrahydrofuran was hydrogenated at 10 psi over Raney nickel catalyst. After 2.5 hours, the catalyst was removed by filtration and the solvent was evaporated to give 1.76 g of crystalline 6-amino-2-(1-methyl-4-piperidyl)indan-1-one. To a solution of 1.04 g (0.00426 mol) of the 6-amino compound in 20 mL of methylene chloride and 3.4 g of pyridine was added 0.61 g (0.005 mol) of methanesulfonyl chloride. The mixture was stirred at room temperature for two hours, after which time it was poured onto water and made basic by the addition of a saturated sodium bicarbonate solution. The mixture was concentrated to dryness in *vacuo*, and the solid residue was extracted with two 50 mL portions of methylene chloride. Evaporation of the methylene chloride gave 1.56 g of 6-methanesulfonamido-2-(1-methyl-4-piperidyl)indane-2-one as a colorless foam.

Step B: Preparation of 6-Methanesulfonamido-2-(4-piperidyl)indan-1-one hydrochloride

30 To a solution of 1.35 g (0.00419 mol) of 6-methanesulfonamido-2-(1-methyl-4-piperidyl)indan-1-one in 46 mL of 1,2-dichloroethane was added 1.35 g (0.0063 mol) of 1,8-bis(dimethylamino)naphthalene. The solution was cooled in an ice bath and 1.80 g (0.0126 mol) of 1-chloroethylchloroformate was added dropwise over 5 minutes. The mixture was allowed to warm to room temperature and then was refluxed for 5 hours. The cooled mixture was filtered through a small column of silica gel using methylene chloride to wash the column. The eluate was evaporated in *vacuo*. The residual 1.35 g of thick oil was dissolved in 10 mL of methanol, and the solution was refluxed for 24 hours. Evaporation of the methanol and crystallization of the residue from methanol afforded 6-methanesulfonamido-2-(4-piperidyl)indan-1-one hydrochloride as a hemi methanol solvate salt: mp 254-256 ° (dec.).

Anal. Cal'd. for $C_{15}H_{20}N_2O_3S\cdot HCl\cdot 0.5CH_3OH$: C, 51.58; H, 6.42; N, 7.76. Found: C, 51.69; H, 6.36; N, 8.00.

Step C: Preparation of 6-Methanesulfonamido-2-(1-[4-methanesulfonamidophenethyl]-4-piperidyl)-indan-1-one hydrochloride methanol solvate

45 A mixture of 0.100 g (0.00029 mol) of 6-methanesulfonamido-2-(4-piperidyl)indan-1-one hydrochloride, 0.073 g (0.00087 mol) of sodium bicarbonate, 0.128 g (0.00044 mol) of 4-methanesulfonamidophenethyl alcohol mesylate, 15 mg of potassium iodide, and 10 mL of acetonitrile was stirred and refluxed for 32 hours. The cooled solution, transferred to a separatory funnel using 25 mL of ethyl acetate, was washed with water and then with brine. The organic phase was extracted with three 4 mL portions of 1N HCl. The 50 combined acid extracts were made basic by addition of solid sodium bicarbonate, and the basic phase was extracted with three 30 mL portions of ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure to afford 0.125 g (86%) of product. A hydrochloride salt was prepared in methanol; mp 130-135 ° (foams).

Anal. Cal'd. for $C_{24}H_{31}N_3O_5S_2\cdot HCl\cdot CH_3OH$: C, 52.29; H, 6.32; N, 7.32. Found: C, 52.64; H, 6.43; N, 7.03.

55

EXAMPLE 24**1-(Indole-5-carbonyl)-4-phenethylpiperazine**

Indole-5-carboxylic acid (57 mg, 0.35 mmol) was dissolved in THF(2 ml) and DMF (1 drop), then oxalyl chloride (37 μ l 54 mg, 0.42 mmol) was added. The mixture was stirred at room temperature for 3 hours, the solvent was evaporated under reduced pressure and the residue was dissolved in DMF (2 ml) and added to a stirred solution of 1-phenethylpiperazine (66 mg, 0.35 mmol) and diisopropylethylamine (91 μ l, 68 mg, 0.52 mmol) in dichloromethane (1 ml). The mixture was stirred at room temperature for 24 hours, then the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_3$; 95:5:0.5 and crystallized from EtOAc/hexane to give the piperazine as microcrystals (32 mg, 27%), mp 105-108 $^{\circ}\text{C}$.

$\delta_{\text{H}}(\text{CDCl}_3)$ 8.47 (1H, br s), 7.73 (1H, s), 7.38 (1H, d J 8.4 Hz), 7.32-7.19 (7H, m), 6.56 (1H, br s), 3.7 (4H, br s), 2.81 (2H, m), 2.65 (2H, m), and 2.6 (4H, br s).

Elemental analysis for $\text{C}_{21}\text{H}_{22}\text{N}_3\text{O} \cdot 0.4\text{H}_2\text{O}$:
 Calculated: C, 74.05; H, 7.04; N, 12.34%. Found: C, 74.12; H, 6.78; N, 12.36%.

EXAMPLE 25

15 1-(Indole-5-carbonyl)-4-[2-(4-methanesulfonamidophenyl)ethyl]piperazine

In the manner described in Example 24, indole-5-carboxylic acid (100 mg, 0.62 mmol) and 1-[2-(4-methanesulfonamidophenyl)ethyl]piperazine (180 mg, 0.64 mmol) gave, after purification by flash column chromatography on silica gel, eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_3$; 95:5:0.5 and trituration with hexane/EtOAc, the piperazine (68 mg, 26%), mp 94-97 $^{\circ}\text{C}$. Elemental analysis for $\text{C}_{22}\text{H}_{26}\text{N}_4\text{O}_3\text{S} \cdot 0.5\text{H}_2\text{O}$:
 Calculated: C, 60.66; H, 6.26; N, 12.86%. Found: C, 61.02; H, 6.19; N, 12.51%.

EXAMPLE 26

16 1-(Indole-5-carbonyl)-4-[2-(4-nitrophenyl)ethyl]-piperazine

In the manner described in Example 24, indole-5-carboxylic acid (100 mg, 0.62 mmol) and 1-[2-(4-nitrophenyl)ethyl]piperazine (151 mg, 0.64 mmol) gave, after purification by flash column chromatography on silica gel, eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_3$; 95:5:0.5 and trituration with hexane/EtOAc, the piperazine (38 mg, 16%), mp 204-206 $^{\circ}\text{C}$.
 Elemental Analysis for $\text{C}_{19}\text{H}_{22}\text{N}_4\text{O}_3 \cdot 0.5\text{H}_2\text{O}$:
 Calculated: C, 65.09; H, 6.00; N, 14.46%. Found: C, 65.14; H, 5.77; N, 14.38%.

EXAMPLE 27

17 1-(5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(4-nitrophenethyl)piperazine

A solution 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carboxylic acid (850 mg, 3.9 mmoles) in DMF (5 mL) was treated with solid carbonyldiimidazole (772 mg, 4.76 mmole) at room temperature. The reaction was stirred at room temperature until all of the solid dissolved and 4-nitrophenylethyl piperazine (1.05 g, 4.76 mmoles) was then added in one portion and the reaction stirred at room temperature overnight.
 The reaction was poured into 100 mL H_2O and extracted with ethyl acetate. The ethyl acetate solution was dried over MgSO_4 , filtered and concentrated in vacuo. The residue was chromatographed on silica gel eluting with 10% MeOH/chloroform to give 750 mg product which solidified on standing. The product was recrystallized from $\text{CH}_2\text{Cl}_2/\text{ethanol}$ to give 640 mg; mp 176 $^{\circ}\text{C}$.
 Elemental analysis for $\text{C}_{20}\text{H}_{20}\text{N}_3\text{O}_4\text{S}_2$. Calculated: C, 55.79; H, 4.68; N, 9.76. Found: C, 55.76; H, 5.03; N, 9.76.

The compounds of the following Examples 28 and 29 were prepared in a manner analogous to that described in Example 27.

EXAMPLE 28

18 1-(5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(2-(2-pyridinyl)ethyl)piperazine dihydrochloride

Elemental analysis for $\text{C}_{19}\text{H}_{20}\text{N}_3\text{O}_2\text{S}_2 \cdot 2\text{HCl} \cdot 1/4\text{H}_2\text{O}$: Calculated: C, 49.18; H, 4.88; N, 9.05. Found: C, 49.28; H, 5.02; N, 9.13; mp. 210 $^{\circ}\text{C}$.

EXAMPLE 29

19 1-(5,6-Dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(4-nitrobenzyl)piperazine

Elemental analysis for $\text{C}_{19}\text{H}_{18}\text{N}_3\text{O}_4\text{S}_2 \cdot 1/4\text{H}_2\text{O}_2$:

Calculated: C, 54.20; H, 4.42; N, 9.98. Found: C, 54.40; H, 4.49; N, 10.02. mp 182 $^{\circ}\text{C}$.

EXAMPLE 30

5-Methanesulfonamido-3-(1-[2-pyridylethyl]-4-piperidinyl-carbonyl)benzothiophene hydrogen oxalate

A solution of 5.00 g (0.028 mol) of 5-nitrobenzothiophene (Bordwell, J. Am. Chem. Soc., 77, 5939 (1955)) in 175 mL of ethanol was hydrogenated at 50 psi over 0.5 g of 10% Pd/c for 1.5 hours. The catalyst was removed by filtration, and the solvent was removed under reduced pressure. The residue, 4.39 g, was dissolved in a mixture of 8.4 g of pyridine and 50 mL of methylene chloride. The solution, treated with 3.45 g (0.03 mol) of methanesulfonyl chloride, was stirred overnight at room temperature. The solution was washed with water, dried over MgSO_4 , filtered, and the solvent removed under reduced pressure to give

10 1.74 g of crystalline 5-methanesulfonamidobenzothiophene.

To a suspension of 3.86 g (0.029 mol) of anhydrous aluminum chloride in 7 mL of methylene chloride was added 1.74 g (0.0078 mol) of 5-methanesulfonamidobenzothiophene followed by the careful addition of a solution of the acid chloride of 1-benzoyl-isonicotinic acid. (The latter solution was prepared by stirring 1.81 g of 1-benzoylisonicotinic acid with 3 mL of thionyl chloride and 3 drops of DMF for 18 hours, 15 evaporating the solvents, and dissolving the residue in 10 mL of CH_2Cl_2 .) The aluminum chloride reaction mixture was stirred vigorously at reflux for 2 hours, cooled, and poured onto 25 g of ice. The oil that precipitated was extracted into ethyl acetate. Evaporation of the ethyl acetate afforded 2.34 g of yellow foam. This material was stirred and refluxed with 30 mL of methanol and 45 mL 6N hydrochloric acid for 8 hours. Evaporation of the solvents and trituration of the residue with hot absolute ethanol gave 0.80 g of 5-

20 methanesulfonamido-3-[(4-piperidinyl)-carbonyl]benzothiophene hydrochloride; mp 259-261 °C.

A mixture of 0.80 g (0.00213 mole) of the piperidine derivative, 0.45 g (0.00427 mol) of 2-vinylpyridine, 0.435 g (0.0032 mol) of sodium acetate trihydrate, 2 mL of water and 2 mL of methanol was stirred and refluxed for 15 hours. The solution was evaporated to dryness and the residue was purified by flash 25 chromatography on silica gel using 5% CH_3OH in chloroform saturated with ammonia as an eluent. The chromatographically homogeneous fractions were combined. An oxalate salt, prepared in isopropyl alcohol-ethanol, was recrystallized from water to give the title compound, mp. 206-208 °C.

Anal. Calc'd. for $\text{C}_{22}\text{H}_{25}\text{N}_3\text{O}_3\text{S}_2 \cdot 2\text{C}_2\text{H}_2\text{O}_4$: C, 50.07; H, 4.69; N, 6.74. Found: C, 50.05; H, 4.61; N, 6.76.

30 EXAMPLE 31

6-Methanesulfonamido-2-(1-[4-methanesulfonamidophenoxy ethyl]-4-piperidyl)indan-1-one oxalate hydrate.

Employing the procedures substantially as described in Example 23, Step C but employing the appropriate starting materials, the title compound was obtained.

35 Elemental analysis for $\text{C}_{24}\text{H}_{31}\text{N}_3\text{O}_6\text{S}_2 \cdot (\text{COOH})_2 \cdot \text{H}_2\text{O}$ Calculated: C, 49.59; H, 5.60; N, 6.67. Found: C, 49.61; H, 5.27; N, 6.56. mp. 130-135 °C.

EXAMPLE 32

In Vitro Test for Class III Antiarrhythmic Activity

40 Purpose:

This in vitro assay is designed to assess possible potassium channel blocking activity of a compound based on its ability to prolong effective refractory period (ERP) in isolated papillary muscle.

45 Tissue Preparation:

Ferrets (700 to 1200 grams) are anesthetized with 0.7 ml of a mixture of xylazine and ketamine HCl in 1:7 ratio. Papillary muscles from the right ventricle are quickly excised from the isolated heart and mounted in 50 mL organ baths containing Krebs-Henseleit solution (pH = 7.2-7.4) at 37 °C. The composition of the 50 solution in millimoles per liter, are as follows: NaCl , 118; KCl , 4.7; NaHCO_3 , 23; $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 2.0; $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 1.2; KH_2PO_4 , 1.2; Dextrose, 11.1. Timolol (10^{-7}M) is added to the solution to block the effects of catecholamines released during stimulation of the muscles. This solution is aerated with 95% O_2 and 5% CO_2 . The tissue is stimulated at 1 Hz at one msec pulse duration by a square wave stimulator at a voltage 30% above threshold through platinum electrodes that touch the tissue just above the bottom attachment 55 point. The tendinous end of the tissue is connected by thread to an isometric force transducer leading to a polygraph.

Effective Refractory Period (ERP) Measurement:

The ERP is determined by a standard 2 pulse protocol. Both pulses are stimulated at 1.3 x voltage threshold. While pacing the tissue at a basal frequency of 1 Hz, a single extrastimulus is delivered after a variable time delay. The shortest delay resulting in a propagated response is defined as the ERP.

5

Protocol:

1. Tissues are mounted with a resting tension of 0.5 gms, stimulated at 1 Hz, and allowed to equilibrate for 2 hours with washings at 15-20 minute intervals.
- 10 2. Voltage is adjusted to 30% above threshold and resting tension is adjusted for maximum developed tension, and the tissue is allowed 5 min. reequilibration time.
3. Effective refractory period is measured at 1 Hz. Changes in resting tension and developed force are noted.
- 15 4. After equilibration, ERP's and developed force are measured at 30 minutes following the addition of increasing cumulative concentrations for test agent to the organ bath. Four to five concentrations of test agents were used to generate a concentration-response curve.
5. Four tissues per compound are tested.

Results:


20 Employing the above protocol it has been found that the effective concentration of most of the compounds of this invention required to increase the refractory period by an increment of 25% above baseline is less than or equal to 10 micromolar, i.e. $EC_{25} \leq 10 \mu M$, whereas sotalol in the same protocol has an $EC_{25} \sim 20 \mu M$.

25

Claims

1. Compounds of structural formula:

30



35

or a pharmaceutically acceptable salt thereof, wherein:

Ar is an aromatic ring selected from; 1) benzo, 2) thieno, 3) furo, and 4) pyrrolo;

B is benzo or other carbocyclic or heterocyclic moiety of 5-7 members fused to the aromatic ring, Ar, with up to 3 variable members independently selected from:

- 1) $S-(O)_p$, wherein p is 0, 1 or 2,
- 2) $C(R)_2$ wherein the R groups are the same or different and represent hydrogen or C_{1-6} alkyl,
- 3) $C=O$,
- 4) $CHOR$,
- 5) $-O-$ and
- 6) NR

Q is a 5-7 membered heterocycle with one or two nitrogen atoms selected from piperidine, piperazine, pyrrolidine, imidazolidine, hexahydroazepine, hexahydrodiazepine and imidazole,

X is $-CO-$, $-CO-NR-(CR_2)_m-$, $-SO_2-$ or $-(CR_2)_m-$;

Y is $-(CR_2)_mO-$; wherein m is 0, 1, 2 or 3;

R^1 is hydrogen if Q is imidazolyl or if Q is other than imidazolyl, R^1 is pyridyl, benzimidazolyl, pyrimidinyl, phenyl, naphthyl, thiophenyl, thiazolyl, pyrazinyl, quinolinyl, quinoxalinyl, indolyl, or benzofuranyl, either unsubstituted or substituted with one or more of R^2 , R^3 or R^5 .

55 wherein:

R^5 is

- 1) $-N(R)SO_2 C_{1-6}$ alkyl,
- 2) $-N(R)SO_2(CH_2)_mCO_2 C_{1-6}$ alkyl,

- 3) $-\text{NO}_2$;
- 4) $-\text{N}(\text{R})\text{COC}_1-\text{6alkyl}$,
- 5) $-\text{N}(\text{R})\text{SO}_2-\text{C}_6\text{H}_4-\text{R}$
- 6) $-\text{N}(\text{R})\text{COC}_6\text{H}_4\text{R}$
- 7) $-\text{C}_2-\text{6alkanoyl}$,
- 8) $\text{CON}(\text{R})_2$
- 9) $-\text{CN}$,
- 10) $-\text{CO}_2\text{C}_1-\text{6alkyl}$
- 11) benzoyl, either unsubstituted or substituted with $\text{C}_1-\text{6alkyl}$, $\text{C}_1-\text{6alkoxy}$, halo, or hydroxy,
- 12) $-\text{NRCOO}(\text{C}_1-\text{6alkyl})$,
- 13) $-\text{NRCOOphenyl}$ either unsubstituted or substituted with $\text{C}_1-\text{6alkyl}$, $\text{C}_1-\text{6alkoxy}$, hydroxy or halo,
- 14) $-\text{NRCON}(\text{R})_2$,
- 15) $-\text{S}(\text{O})_p\text{C}_1-\text{6alkyl}$, wherein p is 0, 1 or 2,
- 16) $-\text{S}(\text{O})_p\text{phenyl}$, either unsubstituted or substituted with $\text{C}_1-\text{6alkyl}$, $\text{C}_1-\text{6alkoxy}$, hydroxy, or halo,
- 17) phenyl, either unsubstituted or substituted with $\text{C}_1-\text{6alkyl}$, $\text{C}_1-\text{6alkoxy}$, halo, or hydroxy,
- 18) imidazolyl, or
- 19) $-\text{SO}_2\text{N}(\text{R})_2$;

R^2 and R^3 are independently selected from:


- 1) hydrogen,
- 2) $\text{C}_1-\text{3alkyl}$ either unsubstituted or substituted with
 - a) $-\text{N}(\text{R})_2$
 - b) $\text{CON}(\text{R})_2$
 - c) $-\text{CO}(\text{C}_1-\text{6alkyl})$,
 - d) $-\text{O}(\text{C}_1-\text{6alkyl})$,
 - e) $-\text{OH}$, or
 - f) $-\text{S}(\text{O})_p(\text{C}_1-\text{6alkyl})$;
- 3) $\text{C}_1-\text{3alkoxy}$,
- 4) $-\text{N}(\text{R})_2$,
- 5) halo or
- 6) CF_3 .

35 with the proviso that if R^1 is phenyl, with other than an R^5 substituent, then one of R^2 or R^3 in the


R^2
 R^3 ---
 $\text{Ar}-[\text{B}]-\text{moiety is R}^5$

45 2. The compound of claim 1 wherein B has the structure;

5




10



15


wherein W is

20




25 3. The compound of Claim 2 wherein B has the structure:

30



35



40

4. The compound of Claim 3 wherein R¹ is pyridyl, benzimidazolyl, pyrimidinyl or phenyl, either unsubstituted or substituted with up to three substituents selected from R², R³ and R⁵.
- 45 5. The compound of Claim 4 wherein R¹ is 2-pyridyl, 6-methyl-2-pyridyl or 4-methanesulfonamidophenyl.
6. The compound of Claims 1 through 5 wherein Q is piperazine or piperidine.
7. A compound selected from:
 - 50 2-[1-(2-pyridylethyl)-4-piperidyl]-1-indanone;
 - 2-[1-(4-nitrophenethyl)-4-piperidyl]-1-indanone;
 - 55 2-[1-(4-methanesulfonamidophenethyl)-4-piperidyl]-1-indanone;
 - 4-{{[4-(2-pyridylethyl)]-1-piperazinyl}-thiochromane;

4-{[4-(*p*-nitrophenethyl)-1-piperazinyl]} thiochramane;
N-{4-(4-thiochromanyl)-1-piperazinyl}-ethyl[phenyl]methanesulfonamide;
5 2-[4-(4-nitrophenethyl)-piperazin-1-yl]-1-tetralone;
1-hydroxy-2-[4-(4-nitrophenethyl)piperazin-1-yl]tetralin; and
10 5,6-dihydro-5-[4'-(2-(2-pyridyl)ethyl)-piperazin-1'yl]methylthieno[2,3-b]thiopyran-4-one; or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical formulation comprising a carrier and an effective antiarrhythmic amount of a compound of Claim 1.

15 9. The use of a compound of Claim 1 for the manufacture of a medicament suitable for treating arrhythmia and atrial and ventricular fibrillation in a patient with myocardial infarction, thereby preventing sudden death.

20

25

30

35

40

45

50

55



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 431 945 A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 90313264.5

⑭ Date of filing: 06.12.90

⑮ Int. Cl.5: **C07D 401/06, C07D 409/12,
C07D 495/04, C07D 335/06,
C07D 295/116, C07D 213/38,
A61K 31/445, A61K 31/395,
C07D 409/14, C07D 211/32,
C07D 295/096**

⑯ Priority: 08.12.89 US 447949

⑰ Date of publication of application:
12.06.91 Bulletin 91/24

⑱ Designated Contracting States:
CH DE FR GB IT LI NL

⑲ Date of deferred publication of the search report:
22.04.92 Bulletin 92/17

⑳ Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway New Jersey 07065-0900(US)


㉑ Inventor: Baldwin, John J.
621 Gypsy Hill Circle
Gwynedd Valley, PA 19437(US)
Inventor: Claremon, David A.
809 Mockingbird Lane
Audubon, PA 19403(US)
Inventor: Elliott, Jason M.
74 Ramsgate Court
Blue Bell, PA 19422(US)
Inventor: Ponticello, Gerald S.
2045 Spring Valley Road
Lansdale, PA 19446(US)
Inventor: Remy, David C.
607 Jenkins Lane, MR1
North Wales, PA 19454(US)
Inventor: Selnick, Harold G.
1232 Lois Road
Ambler, PA 19002(US)

㉒ Representative: Hesketh, Alan, Dr. et al
European Patent Department Merck & Co.,
Inc. Terlings Park Eastwick Road
Harlow Essex, CM20 2QR(GB)

EP 0 431 945 A3

㉓ Antiarrhythmic agents.

㉔ Compounds of structural formula:



wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members and Q is a nitrogen containing heterocycle, are antiarrhythmic agents.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

Application Number

EP 90 31 3264

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	EP-A-0 208 235 (MERRELL DOW PHARMACEUTICAL, INC.) ---		C 07 D 401/06 C 07 D 409/12 C 07 D 495/04 C 07 D 335/06 C 07 D 295/116 C 07 D 213/38 A 61 K 31/445 A 61 K 31/395 C 07 D 409/14 C 07 D 211/32 C 07 D 295/096
A	EP-A-0 260 901 (AMERICAN HOME PRODUCTS CORPORATION) ---		
A	EP-A-0 242 173 (PFIZER LTD) ---		
A	EP-A-0 296 560 (EISAI CO., LTD) ---		
D,A	EP-A-0 300 908 (RHONE-POULENC SANTE) ---		
D,A	US-A-4 788 196 (PFIZER INC.) ---		
D,A	EP-A-0 285 323 (PFIZER LTD) ---		
D,A	US-A-4 806 536 (PFIZER INC.) ---		
D,A	EP-A-0 235 752 (EISAI CO., LTD) -----		
INCOMPLETE SEARCH			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely : 7 Claims searched incompletely : 1-6, 8-9 Claims not searched : Reason for the limitation of the search:</p> <p>As the drafting of the claims is not clear and concise (Art. 83-84, EPO) and encompasses such an enormous amount of products, a complete search is not possible on economic grounds (see Guidelines for Examination in the EPO, Part B, Chapter III,2). So the search has been based (Rule 45) on the examples.</p>			C 07 D A 61 K
Place of search		Date of completion of the search	Examiner
THE HAGUE		04-02-1992	DE BUYSER I.A.F.
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			